164
Participants
Start Date
July 11, 2022
Primary Completion Date
April 30, 2027
Study Completion Date
December 31, 2027
RBS2418
RBS2418 is a potent and selective small molecule inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1). RBS2418 as monotherapy potentially can have an activating effect on the anti-tumor innate immune response and lead to anti-tumor responses in adult subjects with advanced or metastatic tumors.
Pembrolizumab
200 mg intravenously every 3 weeks
Other approved anti-cancer therapy
Standard of care (SOC) therapy
RECRUITING
Ichan School of Medicine at Mount Sinai, New York
RECRUITING
Christiana Care Health Services, Newark
RECRUITING
American Oncology Partners of Maryland, Bethesda
RECRUITING
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
ACTIVE_NOT_RECRUITING
NEXT Virigina, Fairfax
ACTIVE_NOT_RECRUITING
Carolina BioOncology Institute, Huntersville
RECRUITING
Vanderbilt-Ingram Cancer Center, Nashville
RECRUITING
Norton Cancer Institute, Louisville
RECRUITING
Ochsner Clinic Foundation, New Orleans
WITHDRAWN
Tranquil Research, Webster
RECRUITING
Honor Health Research Institute, Scottsdale
RECRUITING
University of Arizona, Tucson
RECRUITING
UCLA Hematology/Oncology - Santa Monica, Santa Monica
RECRUITING
Stanford Cancer Institute, Palo Alto
Riboscience, LLC.
INDUSTRY